Page last updated: 2024-09-05

solifenacin succinate and Cardiovascular Diseases

solifenacin succinate has been researched along with Cardiovascular Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	1 (33.33)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Hamada, T; Igawa, Y; Kato, D; Katoh, T; Kuroishi, K; Yamaguchi, O	1
Athanasiou, S; Cambronero Santos, J; Chapple, CR; Drake, MJ; Esen, A; Herschorn, S; Huang, M; MacDiarmid, S; Mitcheson, D; Siddiqui, E; Stoelzel, M	1
de la Rosette, JJ; Michel, MC; Vogel, M; Wetterauer, U	1

Trials

2 trial(s) available for solifenacin succinate and Cardiovascular Diseases

Article	Year
Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. Lower urinary tract symptoms, 2020, Volume: 12, Issue:1 Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents	2020
Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). International journal of clinical practice, 2017, Volume: 71, Issue:5 Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive	2017

Article

Year

Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study.

Lower urinary tract symptoms, 2020, Volume: 12, Issue:1

Topics: Acetanilides; Aged; Aged, 80 and over; Benzilates; Cardiovascular Diseases; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Imidazoles; Japan; Male; Middle Aged; Muscarinic Antagonists; Solifenacin Succinate; Thiazoles; Tolterodine Tartrate; Treatment Outcome; Urinary Bladder, Overactive; Urological Agents

2020

Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE).

International journal of clinical practice, 2017, Volume: 71, Issue:5

Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Muscarinic Antagonists; Single-Blind Method; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive

2017

Other Studies

1 other study(ies) available for solifenacin succinate and Cardiovascular Diseases

Article	Year
Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. Drug safety, 2008, Volume: 31, Issue:6 Topics: Aged; Aged, 80 and over; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Female; Germany; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Product Surveillance, Postmarketing; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines	2008

Article

Year

Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study.

Drug safety, 2008, Volume: 31, Issue:6

Topics: Aged; Aged, 80 and over; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Female; Germany; Heart Rate; Humans; Male; Middle Aged; Muscarinic Antagonists; Product Surveillance, Postmarketing; Quinuclidines; Solifenacin Succinate; Tetrahydroisoquinolines

2008